Corticosteroid Side Effects and Clinical Considerations

Introduction to Side Effect Profiles

The European League Against Rheumatism (EULAR) and American College of Rheumatology (ACR) guidelines state that there is insufficient evidence demonstrating a meaningful difference in adverse events between methylprednisolone and prednisolone, except for weight gain, which is reduced with intramuscular methylprednisolone 1, 2, 3

Weight gain was the only side effect shown to be reduced with intramuscular methylprednisolone compared to oral prednisolone 1, 2, 3
No statistically significant reduction in other glucocorticoid-related adverse events was demonstrated 1, 2, 3
Long-term safety benefits of methylprednisolone over prednisolone remain unknown 1, 2, 3

Both medications carry the same class-wide risks, including metabolic effects (hyperglycemia, diabetes, weight gain, dyslipidemia), musculoskeletal effects (osteoporosis, fractures, myopathy), cardiovascular effects (hypertension, cardiovascular disease), ophthalmologic effects (cataracts, glaucoma), and gastrointestinal effects (peptic ulcer disease) 1, 2, 4

The EULAR/ACR guidelines suggest intramuscular methylprednisolone may be considered in specific scenarios, such as female patients with difficult-to-control comorbidities, patients with hypertension, diabetes, osteoporosis, or glaucoma, and situations where a lower cumulative dose is desirable 1, 2, 3
Assess baseline risk factors for glucocorticoid toxicity, including diabetes, hypertension, osteoporosis, glaucoma, and peptic ulcer disease 1, 2, 4

Both medications require identical monitoring for blood glucose and diabetes development, blood pressure, bone density and fracture risk, ophthalmologic complications, and signs of infection or immunosuppression 1, 2, 4, 5